11,476 results match your criteria Parkinson Disease Dementia

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Alzheimers Dement 2021 Jun 20. Epub 2021 Jun 20.

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.

Introduction: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD).

Methods: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p-tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER-1, BioFINDER-2).

Results: In CU, a combination of plasma Aβ42/Aβ40 and p-tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0. Read More

View Article and Full-Text PDF

Exposure to anesthesia is not associated with development of α-synucleinopathies: A nested case-control study.

Parkinsonism Relat Disord 2021 Jun 8;88:76-81. Epub 2021 Jun 8.

Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address:

Introduction: Preclinical studies suggest that inhalational anesthetics may induce neuropathology changes in the nigrostriatal system, leading to development of α-synucleinopathies. We explored the role of general anesthesia in the development of Parkinson disease (PD) and other α-synucleinopathies.

Methods: All α-synucleinopathy cases in Olmsted County, Minnesota, from January 1991, to December 2010, were identified from diagnostic codes, and then reviewed for type and index date of diagnosis. Read More

View Article and Full-Text PDF

Exploring the experiences of living with Lewy body dementia: An integrative review.

J Adv Nurs 2021 Jun 19. Epub 2021 Jun 19.

International Observatory on End of Life Care, Division of Health Research, Faculty of Health and Medicine, Health Innovation One, Lancaster University, Lancaster, UK.

Aim: Lewy body dementia is a common neurodegenerative dementia with unique challenges in managing day-to-day life. A more in-depth multifaceted picture of the Lewy body dementia lived experience will enable identification of best practice and future research direction. The review aim was to explore experiences of people living with Lewy body dementia and their family carers. Read More

View Article and Full-Text PDF

In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.

Parkinsonism Relat Disord 2021 May 31;88:68-75. Epub 2021 May 31.

Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. Electronic address:

Introduction: We aimed to assess associations between multimodal neuroimaging measures of cholinergic basal forebrain (CBF) integrity and cognition in Parkinson's disease (PD) without dementia.

Methods: The study included a total of 180 non-demented PD patients and 45 healthy controls, who underwent structural MRI acquisitions and standardized neurocognitive assessment through the PD-Cognitive Rating Scale (PD-CRS) within the multicentric COPPADIS-2015 study. A subset of 73 patients also had Diffusion Tensor Imaging (DTI) acquisitions. Read More

View Article and Full-Text PDF

Multitarget therapeutic approaches for Alzheimer's and Parkinson's disease: an opportunity or an illusion?

Future Med Chem 2021 Jun 17. Epub 2021 Jun 17.

Centro de Investigação em Química da Universidade do Porto/Department of Chemistry & Biochemistry, Faculty of Sciences, University of Porto, Porto, 4169-007, Portugal.

Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative diseases and the leading causes of dementia worldwide. The etiology of these multifactorial pathologies is not completely known. The available therapeutic approaches can cause temporary relief of symptoms but cannot slow down their progression or cure them. Read More

View Article and Full-Text PDF

Unexpected Findings During Double-blind Discontinuation of Acetylcholinesterase Inhibitor Medications.

Clin Ther 2021 Jun 12. Epub 2021 Jun 12.

Puget Sound Veterans Affairs Medical Center, Seattle, Washington; The Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington. Electronic address:

Purpose: The long-term effects of acetylcholinesterase inhibitors (AChEIs) used in the treatment of patients with various types of dementia remain unclear, largely due to challenges in the study of their discontinuation. We present several unexpected results from a discontinuation trial that might merit further investigation.

Methods: This double-blind, placebo-controlled study of the discontinuation of AChEI medications was conducted in 62 US veterans. Read More

View Article and Full-Text PDF

R869C mutation in molecular motor gene is involved in dementia with Lewy bodies.

Alzheimers Dement (Amst) 2021 4;13(1):e12143. Epub 2021 Jun 4.

The Genomic Research Laboratory for Neurodegeneration, Neurological Institute Tel Aviv Sourasky Medical Center Tel Aviv Israel.

Introduction The: -N370S mutation is one of the most frequent risk factors for dementia with Lewy bodies (DLB) and Parkinson's disease (PD). We looked for genetic variations that contribute to the outcome in N370S-carriers, whether PD or DLB.

Methods: Whole-genome sequencing of 95 Ashkenazi-N370S-carriers affected with either DLB (n = 19) or PD (n = 76) was performed, and 564 genes related to dementia and PD analyzed. Read More

View Article and Full-Text PDF

Long non-coding RNAs in neurodegenerative diseases.

Neurochem Int 2021 Jun 10;148:105096. Epub 2021 Jun 10.

Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Electronic address:

Neurodegenerative diseases are gradually becoming the main burden of society. The morbidity and mortality caused by neurodegenerative diseases remain significant health-care concerns. For most neurodegenerative diseases, there are no effective treatments. Read More

View Article and Full-Text PDF

Odor Recognition Memory in Parkinson's Disease: A Systematic Review.

Front Aging Neurosci 2021 25;13:625171. Epub 2021 May 25.

Department of Neurology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Olfactory impairment is a central non-motor symptom in Parkinson's disease (PD). Previous studies have demonstrated that olfactory dysfunction is associated with mental illness and impaired cognition. The frequently investigated olfactory functions are odor detection, discrimination, and identification. Read More

View Article and Full-Text PDF


Adv Food Nutr Res 2021 24;96:251-310. Epub 2021 May 24.

IM Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; Yaroslavl State University, Yaroslavl, Russia. Electronic address:

Since the discovery of manifest Zn deficiency in 1961, the increasing number of studies demonstrated the association between altered Zn status and multiple diseases. In this chapter, we provide a review of the most recent advances on the role of Zn in health and disease (2010-20), with a special focus on the role of Zn in neurodegenerative and neurodevelopmental disorders, diabetes and obesity, male and female reproduction, as well as COVID-19. In parallel with the revealed tight association between ASD risk and severity and Zn status, the particular mechanisms linking Zn and ASD pathogenesis like modulation of synaptic plasticity through ProSAP/Shank scaffold, neurotransmitter metabolism, and gut microbiota, have been elucidated. Read More

View Article and Full-Text PDF

Brain connectivity markers in advanced Parkinson's disease for predicting mild cognitive impairment.

Eur Radiol 2021 Jun 9. Epub 2021 Jun 9.

Department of Neurosurgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, 3002# Sungang West Road, Futian District, Shenzhen, 518035, China.

Objectives: Mild cognitive impairment (MCI) is a well-defined non-motor manifestation and a harbinger of dementia in Parkinson's disease. This study is to investigate brain connectivity markers of MCI using diffusion tensor imaging and resting-state functional MRI, and help MCI diagnosis in PD patients.

Methods: We evaluated 131 advanced PD patients (disease duration > 5 years; 59 patients with MCI) and 48 healthy control subjects who underwent a diffusion-weighted and resting-state functional MRI scanning. Read More

View Article and Full-Text PDF

Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders.

Neurology 2021 Jun 7. Epub 2021 Jun 7.

Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.

Objective: To evaluate whether orthostatic hypotension (OH) or supine hypertension (SH) is associated with brain atrophy and white matter hyperintensities (WMH), we analyzed clinical and radiological data from a large multicenter consortium of patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB).

Methods: Supine and orthostatic blood pressure and structural magnetic resonance imaging data were extracted from PD and DLB patients evaluated at eight tertiary-referral centers in the USA, Canada, Italy, and Japan. OH was defined as a systolic/diastolic BP fall ≥20/10 mm/Hg within 3 minutes of standing from the supine position (severe, ≥30/15 mm/Hg) and SH as a BP ≥140/90 mmHg with normal sitting blood pressure. Read More

View Article and Full-Text PDF

Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease.

Front Neurol 2021 20;12:652424. Epub 2021 May 20.

Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Cognitive impairment is a potential late feature of Parkinson's disease (PD). However, studies in patients with late-stage PD are lacking due to the particular characteristics of this population. To evaluate the frequency of dementia in late-stage PD patients and to assess the impact of using different diagnostic criteria. Read More

View Article and Full-Text PDF

The Human Hippocampus in Parkinson's Disease: An Integrative Stereological and Proteomic Study.

J Parkinsons Dis 2021 Jun 4. Epub 2021 Jun 4.

Neuroplasticity and Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, Ciudad Real, Spain.

Background: Parkinson's disease (PD) is a prevalent neurodegenerative disease that is pathologically described as a six-stage α-synucleinopathy. In stage 4, α-synuclein reaches the hippocampus, inducing cognitive deficits, from which it progresses to the isocortex, leading to dementia. Among hippocampal fields, cornu ammonis 2 is particularly affected by this α-synucleinopathy and critical for cognitive decline. Read More

View Article and Full-Text PDF

Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data.

Sci Rep 2021 Jun 3;11(1):11751. Epub 2021 Jun 3.

Department of Neurology, Parkinson Expertise Center, University Medical Center Groningen, University of Groningen, Hanzeplein 1 AB-51, 9700RB, Groningen, The Netherlands.

Deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM) has been clinically investigated in Alzheimer's disease (AD) and Lewy body dementia (LBD). However, the clinical effects are highly variable, which questions the suggested basic principles underlying these clinical trials. Therefore, preclinical and clinical data on the design of NBM stimulation experiments and its effects on behavioral and neurophysiological aspects are systematically reviewed here. Read More

View Article and Full-Text PDF

Clinical Markers May Identify Patients at Risk for Early Parkinson's Disease Dementia: A Prospective Study.

Am J Alzheimers Dis Other Demen 2021 Jan-Dec;36:15333175211021369

Neurology ward, Clinical Municipal Hospital "dr. G Curteanu" Oradea, Oradea, Romania.

Background: The study aims at identifying features predictive of early onset of dementia in Parkinson's disease (PD).

Methods: 103 non-demented PD patients were evaluated on various scales at baseline and 89 patients at 3-year follow-up.

Results: By the end of the study 43. Read More

View Article and Full-Text PDF

Physical Exercise-Induced Myokines in Neurodegenerative Diseases.

Int J Mol Sci 2021 May 28;22(11). Epub 2021 May 28.

Department of Biological Sciences, Konkuk University, Seoul 05029, Korea.

Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are disorders characterized by progressive degeneration of the nervous system. Currently, there is no disease-modifying treatments for most NDs. Meanwhile, numerous studies conducted on human and animal models over the past decades have showed that exercises had beneficial effects on NDs. Read More

View Article and Full-Text PDF

Interplay of RNA-Binding Proteins and microRNAs in Neurodegenerative Diseases.

Int J Mol Sci 2021 May 18;22(10). Epub 2021 May 18.

Department of Pharmacology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan.

The number of patients with neurodegenerative diseases (NDs) is increasing, along with the growing number of older adults. This escalation threatens to create a medical and social crisis. NDs include a large spectrum of heterogeneous and multifactorial pathologies, such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple system atrophy, and the formation of inclusion bodies resulting from protein misfolding and aggregation is a hallmark of these disorders. Read More

View Article and Full-Text PDF

Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.

Behav Sci (Basel) 2021 May 13;11(5). Epub 2021 May 13.

Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, ON M5T2S8, Canada.

Cognitive impairment is a common non-motor symptom in Parkinson's Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairment (PD-MCI) and dementia (PDD). Beta-amyloid and tau brain accumulation, oxidative stress and neuroinflammation are reported risk factors for cognitive impairment. Read More

View Article and Full-Text PDF

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis.

Int J Mol Sci 2021 May 7;22(9). Epub 2021 May 7.

Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Brain small vessel disease (SVD) refers to a variety of structural and functional changes affecting small arteries and micro vessels, and manifesting as white matter changes, microbleeds and lacunar infarcts. Growing evidence indicates that SVD might play a significant role in the neurobiology of central nervous system (CNS) neurodegenerative disorders, namely Alzheimer's disease (AD) and Parkinson's disease (PD), and neuroinflammatory diseases, such as multiple sclerosis (MS). These disorders share different pathophysiological pathways and molecular mechanisms (i. Read More

View Article and Full-Text PDF

Improving Medication Regimen Recommendation for Parkinson's Disease Using Sensor Technology.

Sensors (Basel) 2021 May 20;21(10). Epub 2021 May 20.

Department of Neurology, Donald and Barbara School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA.

Parkinson's disease medication treatment planning is generally based on subjective data obtained through clinical, physician-patient interactions. The Personal KinetiGraph™ (PKG) and similar wearable sensors have shown promise in enabling objective, continuous remote health monitoring for Parkinson's patients. In this proof-of-concept study, we propose to use objective sensor data from the PKG and apply machine learning to cluster patients based on levodopa regimens and response. Read More

View Article and Full-Text PDF

How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer's Disease and Other Neurodegenerative Disorders.

Int J Mol Sci 2021 May 4;22(9). Epub 2021 May 4.

Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA 94158, USA.

Although it is not yet universally accepted that all neurodegenerative diseases (NDs) are prion disorders, there is little disagreement that Alzheimer's disease (AD), Parkinson's disease, frontotemporal dementia (FTD), and other NDs are a consequence of protein misfolding, aggregation, and spread. This widely accepted perspective arose from the prion hypothesis, which resulted from investigations on scrapie, a common transmissible disease of sheep and goats. The prion hypothesis argued that the causative infectious agent of scrapie was a novel proteinaceous pathogen devoid of functional nucleic acids and distinct from viruses, viroids, and bacteria. Read More

View Article and Full-Text PDF

Proteolytic α-Synuclein Cleavage in Health and Disease.

Int J Mol Sci 2021 May 21;22(11). Epub 2021 May 21.

Flechsig Institute for Brain Research, University of Leipzig, 04103 Leipzig, Germany.

In Parkinson's disease, aggregates of α-synuclein within Lewy bodies and Lewy neurites represent neuropathological hallmarks. However, the cellular and molecular mechanisms triggering oligomeric and fibrillary α-synuclein aggregation are not fully understood. Recent evidence indicates that oxidative stress induced by metal ions and post-translational modifications such as phosphorylation, ubiquitination, nitration, glycation, and SUMOylation affect α-synuclein conformation along with its aggregation propensity and neurotoxic profiles. Read More

View Article and Full-Text PDF

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.

J Manag Care Spec Pharm 2021 Jun;27(6):785-790

Norman Fixel Institute for Neurological Diseases, Department of Neurology, University of Florida, Gainesville.

Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality have not taken into account limitations of data sources nor included comparable populations or comparisons to relevant treatment alternatives. To conduct a comparative pharmacovigilance assessment of pimavanserin vs treatment alternatives and by restricting surveillance data to more representative populations. Read More

View Article and Full-Text PDF

[The role of aluminum and lead in the development of Alzheimer's and Parkinson's diseases].

Arkh Patol 2021 ;83(3):56-61

Research Center of Neurology, Moscow, Russia.

The article summarizes the data available in the literature on the toxic effects of aluminum and lead on the human brain and assesses the relationship of these effects to the etiopathogenesis of the most common neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. The accumulation of ions of these metals in the brain structures leads to chronic intoxication that is manifested by the morphological signs that are typical for Alzheimer's disease, such as deposits of β-amyloid and τ-protein mainly in the frontal and temporal regions of the cortex, and for Parkinson's disease, such as degeneration of dopamine neurons in the substantia nigra and their accumulation of α-synuclein. The most likely forms of participation of aluminum and lead ions in the mechanisms of neurodegeneration are the replacement of bivalent metal ions necessary for brain functioning, oxidative stress initiation, epigenetic modifications of histones, and increased expression of noncoding ribonucleic acids. Read More

View Article and Full-Text PDF

Better Together: How Machine Learning Can Help Clinicians Determine If My Father Will Develop Parkinson Disease Dementia.

John D Port

Radiology 2021 May 25:210420. Epub 2021 May 25.

From the Departments of Radiology and Psychiatry, Mayo Clinic Alix School of Medicine, 200 1st St SW, Rochester, Minn 55905.

View Article and Full-Text PDF

Cortical Thickness from MRI to Predict Conversion from Mild Cognitive Impairment to Dementia in Parkinson Disease: A Machine Learning-based Model.

Radiology 2021 May 25:203383. Epub 2021 May 25.

From the Departments of Radiology (N.Y.S., M.B., K.J.A.) and Neurology (S.W.Y., J.S.K.), College of Medicine, The Catholic University of Korea, Seoul, Korea; Department of Radiology, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea (N.Y.S., K.H., S.K.L.); and Department of Biomedical Engineering, College of Bio and Medical Sciences, Daegu Catholic University, Gyeongbuk, Korea (E.Y., U.Y.).

Background Group comparison results associating cortical thinning and Parkinson disease (PD) dementia (PDD) are limited in their application to clinical settings. Purpose To investigate whether cortical thickness from MRI can help predict conversion from mild cognitive impairment (MCI) to dementia in PD at an individual level using a machine learning-based model. Materials and Methods In this retrospective study, patients with PD and MCI who underwent MRI from September 2008 to November 2016 were included. Read More

View Article and Full-Text PDF

Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers.

Mov Disord 2021 May 20. Epub 2021 May 20.

School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.

Background: Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants.

Objective: The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups. Read More

View Article and Full-Text PDF

Association of Socioeconomic Status With Dementia Diagnosis Among Older Adults in Denmark.

JAMA Netw Open 2021 May 3;4(5):e2110432. Epub 2021 May 3.

Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Importance: Low socioeconomic status (SES) has been identified as a risk factor for the development of dementia. However, few studies have focused on the association between SES and dementia diagnostic evaluation on a population level.

Objective: To investigate whether household income (HHI) is associated with dementia diagnosis and cognitive severity at the time of diagnosis. Read More

View Article and Full-Text PDF